NeuroWiki

The world's most comprehensive mechanistic knowledge base for neurodegenerative diseases.

NeuroWiki maps the causal chains from genes to proteins to pathways to disease, creating a densely connected, evidence-backed knowledge graph spanning Alzheimer's, Parkinson's, CBS, PSP, ALS, FTD, and Huntington's disease. Currently 16,000+ published pages with continuous AI-driven expansion.

Knowledge Base at a Glance

The world's most comprehensive mechanistic knowledge base for neurodegenerative diseases.

NeuroWiki maps the causal chains from genes to proteins to pathways to disease, creating a densely connected, evidence-backed knowledge graph spanning Alzheimer's, Parkinson's, CBS, PSP, ALS, FTD, and Huntington's disease. Currently 16,000+ published pages with continuous AI-driven expansion.

Knowledge Base at a Glance

| Section | Pages | Description |
|---------|------:|-------------|
| [Genes](/genes) | 3,850 | Disease-associated genes, risk variants, GWAS findings, expression patterns |
| [Cell Types](/cell-types) | 3,573 | Neuronal subtypes, glia, immune cells — morphology, markers, disease roles |
| [Proteins](/proteins) | 3,189 | Protein structure, function, aggregation, post-translational modifications |
| [Mechanisms](/mechanisms) | 1,803 | Molecular pathways from protein misfolding to neuronal death |
| [Therapeutics](/therapeutics) | 1,066 | Drug therapies, biologics, gene therapy, clinical interventions |
| [Companies](/companies) | 638 | Pharma, biotech, diagnostics — pipelines, programs, partnerships |
| [Diseases](/diseases) | 514 | Disease pages, subtypes, clinical features, diagnostic criteria |
| [Clinical Trials](/clinical-trials) | 493 | Active and completed trials across all disease areas |
| [Institutions](/institutions) | 311 | Research universities, hospitals, consortia, foundations |
| [Ideas](/ideas) | 233 | Novel therapeutic hypotheses, ranked by evidence strength |
| [Researchers](/researchers) | 216 | Key investigators, their contributions and publications |
| [Experiments](/experiments) | 187 | Proposed experiments with protocols, costs, and rankings |
| [Entities](/entities) | 185 | Cross-cutting molecular entities and complexes |
| [Biomarkers](/biomarkers) | 185 | CSF, blood, PET, digital, and emerging diagnostic markers |
| [Technologies](/technologies) | 160 | Therapeutic platforms — ASOs, gene therapy, antibodies, PROTACs |
| [Events](/events) | 124 | Conferences, workshops — AD/PD, AAIC, CTAD, SfN |
| [Investment](/investment) | 99 | Funding landscape, venture activity, market analysis |
| [Diagnostics](/diagnostics) | 95 | Diagnostic tools, accuracy comparisons, clinical utility |
| [Hypotheses](/hypotheses) | 79 | Testable disease hypotheses with evidence scoring |
| [Gaps](/gaps) | 55 | Knowledge gaps, research opportunities, unmet needs |
| [Brain Regions](/brain-regions) | 54 | Neuroanatomy, vulnerability patterns, circuit dysfunction |
| [Circuits](/circuits) | 39 | Neural circuit models and connectivity |
| [Datasets](/datasets) | 26 | Public datasets for neurodegeneration research |
| [Organizations](/organizations) | 35 | Patient organizations, foundations, societies |
| [Projects](/projects) | 22 | Research initiatives, consortia, funding programs |
| [Models](/models) | 15 | Animal models, cell models, experimental systems |
| [Resources](/resources) | 1 | Research resources, biobanks, data repositories |

Total: 17,299 pages across 27 sections

Disease Focus Areas

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

Corticobasal Syndrome (CBS) / Corticobasal Degeneration (CBD)

Progressive Supranuclear Palsy (PSP)

ALS, FTD, and Huntington's Disease

How NeuroWiki Works

Mechanistic Knowledge Graph

Evidence-Based Content

AI-Driven Continuous Expansion

• Crawling Alzforum, PubMed, and conference proceedings for new findings
• Generating and ranking therapeutic hypotheses
• Designing experimental proposals with detailed protocols and cost estimates
• Tracking clinical trials across all disease areas
• Identifying and filling knowledge gaps

Rankings and Quality Scoring

• [Therapeutic Rankings](/therapeutics/rankings) — efficacy and evidence scoring
• [Company Rankings](/companies/rankings) — pipeline and clinical progress
• [Idea Rankings](/ideas/rankings) — therapeutic hypothesis scoring (10 dimensions)
• [Research Gap Overview](/gaps/overview) — prioritized knowledge gaps

Quick Navigation

By Disease: [Alzheimer's](/diseases/alzheimers-disease) | [Parkinson's](/diseases/parkinsons-disease) | [ALS](/diseases/amyotrophic-lateral-sclerosis) | [FTD](/diseases/frontotemporal-dementia) | [Huntington's](/diseases/huntingtons) | [CBS](/diseases/corticobasal-degeneration) | [PSP](/diseases/progressive-supranuclear-palsy)

By Section: [All Pages](/all-pages) | [Genes](/genes) | [Proteins](/proteins) | [Mechanisms](/mechanisms) | [Therapeutics](/therapeutics) | [Clinical Trials](/clinical-trials) | [Biomarkers](/biomarkers) | [Companies](/companies) | [Technologies](/technologies)

Special: [Therapeutic Ideas](/ideas/overview) | [Experiment Proposals](/experiments) | [Events & Conferences](/events) | [Research Gaps](/gaps/overview) | [Hypotheses](/hypotheses/overview)

Meta: [Tags & Taxonomy](/Meta/tags) | [Organizations](/organizations)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PIEZO1
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD

Related Analyses:

• [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) &#x1f504;
• [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;
• [Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) &#x1f504;
• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;